GPR40 agonist GW9508 or GW-9508 CAS: 885101-89-3 is a synthetic molecule that has shown potential in research studies for its ability to activate G protein-coupled receptor 40 (GPR40). This receptor plays an important role in glucose and lipid metabolism, making it a potential target for the treatment of metabolic disorders such as type 2 diabetes and obesity. In this article, we will explore the chemistry, health benefits, potential effects, mechanism of action, safety, side effects, and dosing information associated with GW9508.
Chemical Name:
GW9508's chemical name is N-(4-(1-(2,4-dichlorophenyl)-2-(methylthio)ethyl)piperazin-1-yl)-4-(difluoromethyl)benzamide.
Molecular Formula:
The molecular formula of GW9508 is C23H26Cl2F2N3OS.
Formula Weight:
The formula weight of GW9508 is 500.45 g/mol.
CAS No:
The CAS number of GW9508 is 885101-89-3.
Top Ten Keywords and Synonyms:
Synonyms:
Health Benefits:
GW9508's potential health benefits are related to its ability to activate GPR40, which plays a key role in glucose and lipid metabolism. Research suggests that GPR40 agonists like GW9508 can improve insulin sensitivity, increase glucose-stimulated insulin secretion, and decrease blood glucose levels, making them promising candidates for the treatment of type 2 diabetes. Additionally, GPR40 agonists have been found to increase energy expenditure and reduce body weight in animal models, suggesting their potential use in treating obesity.
Potential Effects:
In addition to the health benefits mentioned above, GW9508 has been studied for its potential effects on various biological systems. For example, research suggests that GW9508 may have anti-inflammatory properties by reducing the levels of pro-inflammatory cytokines. It may also play a role in regulating lipid metabolism by increasing the oxidation of fatty acids and decreasing the synthesis of triglycerides. Additionally, GW9508 has been found to increase the release of adiponectin, a hormone that regulates glucose and lipid metabolism.
Product Mechanism:
GW9508 activates GPR40, a G protein-coupled receptor that is primarily expressed in pancreatic beta cells and intestinal enteroendocrine cells. When GPR40 is activated, it triggers a signaling cascade that leads to the release of insulin and other hormones that regulate glucose and lipid metabolism. GW9508 has also been found to activate other receptors, including GPR120 and GPR84, which are involved in regulating inflammation and metabolic homeostasis.
Safety:
GW9508 has not been approved for human use by regulatory agencies such as the FDA or EMA. However, preclinical studies suggest that it has low toxicity and is well-tolerated at therapeutic doses. More research is needed to determine its safety profile in humans.
Side Effects:
Like all drugs, GW9508 may have side effects. Some of the side effects observed in animal studies include decreased food intake, increased heart rate, and decreased liver weight. Additional research is needed to determine the potential side effects of GW9508 in humans.
Dosing Information:
There is no established dosing information for GW9508 in humans. Preclinical studies have used doses ranging from 0.1 mg/kg to 10 mg/kg, administered orally or intraperitoneally. Doses may vary depending on the route of administration, disease indication, and other factors.
Conclusion:
GW9508 is a synthetic molecule that activates GPR40, a receptor involved in glucose and lipid metabolism. Research suggests that GPR40 agonists like GW9508 may have therapeutic potential for the treatment of metabolic disorders such as type 2 diabetes and obesity. While it has shown promise in preclinical studies, more research is needed to determine its safety and efficacy in humans
